BioSpace News Archive

Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its AgilonTM moldable bone grafting product.

Heidelberg Pharma AG (FSE: WL6) today announced that the partner University of Texas, MD Anderson Cancer Center, Houston, TX, USA, (MD Anderson), was granted patent rights related to the diagnosis and treatment of patients with RNA polymerase II deletion

Prealize, an artificial intelligence (AI)-enabled health insights company, today announced that Arnold Milstein MD, professor of Medicine and director of the Clinical Excellence Research Center at Stanford University, and Prealize co-founder, will be a featured speaker during a SPARK session at the 2020 HIMSS Global Health Conference & Exhibition, taking place March 9-13 in Orlando.

Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2020 ADDF-Harrington Scholar Award.

Containment Technologies Group, Inc. (www.mic4.com) has introduced the MIC-EDU, an automatic decontaminating pharmaceutical isolator, for pharmacy compounding which has been shown to kill viruses, spores, fungi, mycobacterium and bacteria that may contaminate surfaces and cause diseases

Registration is open for BioNJ’s Tenth Annual BioPartnering Conference, co-sponsored by J.P. Morgan and J&J Innovation.

Masimo announced that its management is scheduled to present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on Wednesday, March 11, 2020 at 4:20 p.m. Eastern Time.

AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today the initiation of a pivotal trial for the treatment of pediatric scald injuries with enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), and Servier, an international pharmaceutical company, today announced the execution of the amendment to the agreement initially signed between the two companies in 2014 and modified in 2019.

Sandy Cayo Extends Association’s Focus on Improving Health in N.J. Communities.